

PCT

BEST AVAILABLE COPY

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification ⁶ : A61K 35/78, 31/70, 31/20, 31/16	A1	(11) International Publication Number: WO 97/33599 (43) International Publication Date: 18 September 1997 (18.09.97)
(21) International Application Number: PCT/US96/10500 (22) International Filing Date: 17 June 1996 (17.06.96) (30) Priority Data: 60/025,173 12 March 1996 (12.03.96) US (71) Applicant: VIVA AMERICA MARKETING, INC. [US/US]; 1239 Victoria Street, Costa Mesa, CA 92627 (US). (72) Inventors: HSIA, Houn, Simon; 73 Monserrat Avenue, Foothill Ranch, CA 92610 (US). FAN, David; 27585 Berdan, Mission Viejo, CA 92691 (US). (74) Agent: CALIA, Kurt, Geoffrey; Covington & Burling, 1201 Pennsylvania Avenue, N.W., P.O. Box 7566, Washington, DC 20044 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.

(54) Title: FISH OIL AND GARLIC NUTRITIVE COMPOSITION

(57) Abstract

The present invention relates to nutritional supplements to the human diet used to increase levels of HDL, and decrease levels of O-LDL, cholesterol, and triglycerides in human blood plasma. More specifically, the present invention teaches a novel nutritional supplements which contain a novel combination of fish oil, garlic, rutin, and capsaicin, as well as methods of preparing the nutritional supplements.

Effect of Fish Oil/ Garlic on Lipid Profile



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

FISH OIL AND GARLIC NUTRITIVE COMPOSITION

Cross-Reference to Related Application

This is a continuation-in-part of co-pending provisional application Ser. No. _____, filed March 12, 1996.

5 BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention provides a novel composition for preventing cardiovascular diseases in the human system, and more specifically to nutritive compositions containing fish oil,
10 garlic, rutin, and capsaicin that reduce the levels of triglycerides, cholesterol, and low density lipoprotein (LDL) in the human blood serum, and increase the levels of high density lipoprotein (HDL) in human blood serum.

2. Background of the Invention

15 In the last few years, scientific literature has provided strong evidence for a bona fide link between micronutrient compositions (such as vitamins, minerals, fish oils, and plant extracts) and cardiovascular disease. For humans of high risk for cardiovascular diseases, realizing an appreciable reduction
20 in the levels of high cholesterol, triglycerides, low density lipoprotein (LDL) in their blood serum is known to be important for reducing the risk of cardiac diseases. It is also known that effecting an increase in the levels of high density lipoprotein (HDL) also provides a significant decrease to the risk of cardiac
25 diseases.

Cardiovascular disease resulting from the buildup of arterial plaque is known to be a leading cause of illness and

death in humans. Arterial plaque is caused by precipitous material formed chiefly of oxidized low density lipoprotein (O-LDL). The buildup of plaque in the form of O-LDL in the arteries is understood to be a factor in ischemic heart disease. Free radical oxidants, many of which come from naturally occurring sources such as sun exposure, metabolism of certain nutrients, exercise, or are otherwise often observed in persons suffering from diabetes and high blood pressure, act to oxidize LDL into its deleterious form, O-LDL. Free radical "scavengers" such as vitamins A, E, C, and selenium are believed to react with these oxidants and render them incapable of oxidation. The inhibitory action of these antioxidants thus inhibits the formation of O-LDL, thereby lowering the levels of arterial plaque deposits in blood vessels. In contrast, the presence of high density lipoprotein (HDL) in the body is understood to have beneficial health effects. Specifically, HDL is known to be a more soluble form of lipoprotein, hence its presence does not significantly contribute to the formation of arterial plaque. In addition, it is known that HDL is able to absorb plaque material and may thus directly reduce the amount of arterial plaque.

3. Description of Prior Art

Essential fatty acids (EFAs) are naturally occurring unsaturated fatty acids with a chain length of 18, 20, or 22 carbon atoms. These EFAs cannot be synthesized by the body, hence, dietary intake of EFAs is required. Two fatty acids which fall within the family of EFAs are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), both of which are commonly found

in fish oils. Epidemiological observations indicate that fish oils reduce platelet aggregation and serum triglycerides which may reduce the risk of myocardial infarction, hypertension, atherosclerosis, and certain types of cancer. [Gerster, H.,
5 Internat. J. Vit. Nutr. Res., 65:3-20 (1994)]. Specifically, it has been shown that EPA and DHA derived from fish oils play important structural roles in membranes of most cells, and influence the fluidity of the cell membranes as expressed by decreased whole-blood viscosity and increased erythrocyte
10 flexibility and deformability [Gerster, cited above]. In addition, EFAs such as EPA and DHA are known precursors of eicosanoids -- a class of compounds which includes prostanoids such as prostaglandins and thromboxanes, leukotrienes, and hydroxy fatty acids. Eicosanoids are known to affect
15 platelet aggregation, permeability and tone of the blood vessel walls, blood pressure, and inflammatory immune reactions. [Gerster, cited above].

Fish oil dietary supplementation is known to have other beneficial health effects. Glycogen storage disease is an
20 inherited disorder, and is often complicated by severe hyperlipoproteinemia and hypercholesterolemia, which increase the risk of premature atherosclerosis and cardiovascular diseases. It has been reported that patients suffering from glycogen storage disease that received 10 grams of fish oil for 3 months
25 experienced a significant decrease in levels of triglycerides in the blood serum (-49%) and cholesterol levels in the blood serum (-23%), and a reduction in LDL levels in the blood serum (-40%), and a significant increase in HDL levels in the blood serum

(+30%). [Levy, E., et al., I. Am. J. Clin. Nutr., 57:922-29 (1993)].

Garlic powder has been proposed to have a number of valuable benefits to the human body as a preventative against cardiovascular diseases. For example, daily ingestion of garlic leads to reduced levels of lipids in human blood serum, increased fibrinolysis and tissue plasminogen activator (t-PA) activity, and decreased plasma fibrogen viscosity, each of which may lessen the likelihood of cardiovascular disease. [Brosche, T. et al., British J. Clin. Practice, Supp. 69:12-19 (1990); Kiesewetter H. et al., British J. Clin. Practice, Supp. 69:24-29 (1990)]. In addition, the daily ingestion of garlic is known to reduce the total levels of cholesterol and triglycerides in human serum, as well as reduce blood pressure peripheral vasodilation. [Auer, W. et al., British J. Clin. Practice, Supp. 69:3-6 (1990)].

Flavonoids are secondary metabolites which are found in edible plants and foodstuffs derived from plants. Flavonoids are widely recognized as having antiallergic, anti-inflammatory, antiviral, antiproliferative and anticarcinogenic activities. [Manach, C., et al. J. Nutr., 125:1911-22 (1995)]. Among flavonoids, flavonols occur most abundantly in plants as possess most of these biological properties. [Manach, cited above]. Flavonols naturally occur as O-glycides, typically having a sugar moiety bound at the C-3 position. Rutin is the principal glycoside form of quercetin, the most abundant flavonol in fruits and vegetables.

Capsaicin is a prominent chemical entity in plants of the *Capsicum* genus, which include chili peppers, red pepper, and

paprika. Capsaicin is actually a class of compounds of branched- and straight-chain alkyl vanillylamides. The antimicrobial and analgesic properties of capsaicin have been known for centuries. In addition, capsaicin-containing products have been used to
5 treat rheumatoid arthritis, osteoarthritis, diabetic neuropathy, postherpetic neuralgia, postmastectomy pain syndrome, cluster headache, and reflex sympathetic syndrome. [Cordell, G. and Araujo, O., Ann. Pharm., 27:330-36 (1993)].

Although compositions used to reduce the risks of
10 cardiovascular disease are known, the present invention comprises a novel combination of fish oil, garlic, rutin, and capsaicin, which achieve this purpose. As such, there remains a need in the art for novel compositions like those of the present invention which may be used to treat or prevent cardiovascular disease and
15 disorders.

SUMMARY OF THE INVENTION

The present invention relates to the use of nutritional supplement compositions to overcome the nutritional deficiencies typically associated with the normal Western diet. The
20 compositions of the present invention are obtained by combining fish oil, garlic powder, rutin, and capsaicin. Specifically, the present invention relates to the daily co-administration of one preparation of fish oil, preferably as a single fish oil lozenge, and a preparation comprised of garlic powder, rutin, and
25 capsaicin, preferably in a single lozenge.

It is therefore an object of the invention to provide nutritious and safe compositions for human consumption as dietary

supplements that contain fish oil, garlic powder, rutin, and capsaicin.

It is another object to provide novel compositions which will increase the levels of HDL in human blood serum.

5 It is a further object of the invention to provide compositions which will decrease levels of O-LDL in human blood serum.

10 It is still another object of the invention to provide compositions which will reduce the levels of cholesterol and triglycerides in human blood serum.

The increase of HDL and the reduction of cholesterol and O-LDL should act to reduce the risk of heart disease in humans. Therefore, it is another object of the present invention to provide for the reduction of the risk of cardiovascular disease
15 by daily administration of the compositions of the invention.

DETAILED DESCRIPTION OF THE INVENTION

Daily doses of the compositions of the present invention are aimed at reducing the rate of occurrence of heart disease and are comprised of: (1) fish oil; (2) garlic powder; (3) rutin; and (4)
20 capsaicin. More specifically, the compositions of the present invention are a combination of a fish oil preparation, preferably in the form of a single fish oil lozenge, and a preparation comprised of garlic powder, rutin, and capsaicin, preferably in the form of a single lozenge which is co-administered with the
25 fish oil lozenge. The preferred weight of the fish oil lozenge is between about 500 mg and about 1500 mg, preferably about 1000 mg. The preferred weight of the garlic lozenge is between about

400 mg and about 1000 mg, and most preferably about 700 mg.

The fish oil preparation component of the compositions of the present invention may be available from commercial sources. [Arista, Pharmachem]. EPA and DHA are the active moieties of the fish oil preparation. The fish oil preparation of the present invention comprises EPA in the amount of about 250 mg to about 350 mg, and most preferably about 300 mg. The remainder of the fish oil preparation comprises from about 150 mg to about 250 mg of DHA, and preferably about 200 mg of DHA. The total weight of the fish oil preparation of the present invention is from about 500 mg to about 1500 mg, and preferably about 1000 mg per fish oil lozenge when in the form of a single fish oil lozenge.

The garlic powder used in the garlic powder, rutin, and capsaicin preparation component of the compositions of the present invention may be obtained from commercially available sources. [Extracts, Ashland, Pure-Gar]. In addition, it is preferable to use a deodorized and aged form of garlic powder. A pharmaceutically acceptable form of garlic powder used in the compositions of the present invention comprises, by weight, from about 100 mg to about 700 mg, and more preferably about 175 mg to about 650 mg, and most preferably 500 mg of deodorized and aged garlic powder per garlic/rutin/capsaicin lozenge when in the form of a single lozenge.

The rutin which is employed in the garlic powder, rutin, and capsaicin preparation component of the compositions of the present invention may also be obtained from commercially available sources. [Westco Chemical, Freeman Industries, Inc.]. The rutin component of the garlic powder, rutin, and capsaicin

preparation comprised, by weight, from about 10 mg to about 150 mg, and most preferably about 100 mg.

5 Capsaicin which is used in the compositions of the present inventions may be commercially obtained. [AllChem, Good Hope Botanicals]. When employed in the garlic powder, rutin, capsaicin preparation of the present invention, the capsaicin component of the compositions of the present invention comprises, by weight, from about 20 mg to about 150 mg, and most preferably about 100 mg of capsaicin.

10 The garlic powder, rutin, and capsaicin components are admixed in the same preparation. This preparation is co-administered with the fish oil preparation -- the two preparations comprising the compositions of the present invention.

15 These preparations may be made by conventional methods. To prepare the compositions of the invention, the above-described fish oil and garlic powder/rutin/capsaicin preparations are combined as the active ingredient in intimate admixture with a suitable carrier according to conventional compounding techniques. This carrier may take a wide variety of forms depending upon the form of preparation desired for administration, e.g., oral, sublingual, nasal, or parenteral.

20 In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. For oral liquid preparations (e.g., suspensions, elixirs, and solutions), media containing for example, water, oils, alcohols, flavoring agents, preservatives, coloring agents and the like may be used. Carriers such as starches, sugars, diluents, granulating agents,

25

lubricants, binders, disintegrating agents, and the like may be used to prepare oral solids (e.g., powders, capsules, pills, tablets, and lozenges). Lozenges are a preferred oral dosage form. Controlled release forms may also be used. Because of
5 their ease in administration, lozenges, tablets, pills, and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be sugar coated or enteric coated by standard techniques.

10 Examples of these additional inactive components which provide for easier oral administration include but are not limited to lemon bioflavonoids [Botanical International, Freeman], parsley powder, d-alpha tocopherol, bee's wax, lecithin, gelatin, purified water, and glycerin. These compounds
15 may be used in creating the lozenges of the novel nutritional supplements.

For parenteral products, the carrier will usually comprise sterile water, although other ingredients may be included, e.g., to aid solubility or for preservation purposes. Injectable
20 suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents, and the like may be employed.

A preferred method for using the present invention is for the user to ingest, daily from about 4 to 8 lozenges of the fish oil preparation, most preferably about 6 lozenges of the fish oil
25 preparation, together with from about 3 to 5 lozenges of the garlic powder, capsaicin and rutin preparation, and most preferably 4 lozenges of the garlic powder, capsaicin and rutin preparation.

The following examples illustrate the preferred embodiments of the present invention. These examples are illustrative only, and do not purport to limit the invention in any fashion.

EXAMPLE 1

5 The effect of the present invention on the human lipid profile was measured. A double blind study carried out at the University of California at Irvine Medical School showed that the proper use of the present invention provides for the following effects in human blood serum: (1) a significant reduction in
10 triglyceride levels; (2) a significant decrease in cholesterol and LDL; and (3) a significant increase in the levels of HDL.

 The protocol followed during this investigation was as follows. Ten subjects participated in a month-long study wherein each subject ingested ten lozenges for each day of the study.
15 The placebo group used 10 nonactive lozenges each day for one month, and the active group ingested 10 lozenges of the present invention each day for one month. Each subject ingested three fish oil lozenges and two garlic powder/rutin/capsaicin lozenges (twice daily) for a total daily ingestion of ten lozenges. The
20 identity of the lozenge was unknown by the subjects, and to the examiner (i.e., a double blind study). Blood serum (approximately 4 cc) was collected at the starting time and again after the completion of one month of usage. A fasting lipid profile was conducted on the plasma samples using a lipid
25 fractionation panel automated system. [Hewlett-Packard Co.]. In addition, measurements of electrolytes (including calcium ion) and glucose levels were made using the Chem 18 automated system.

[Hewlett-Packard Co.]. The results were compared using statistical analytical methods and are shown in the attached Figure 1.

5 These results demonstrate a reduction in plasma triglyceride concentration of 41% in comparison to the placebo. In addition, the cholesterol levels showed a 9% reduction, the LDL levels showed a 7% reduction, and the HDL levels showed a 17% increase.

10 These data provide the basis for evaluating the effectiveness of the present invention in causing an increase in human serum HDL levels and a decrease in the levels of serum cholesterol, triglycerides, and low density lipoprotein (LDL).

EXAMPLE 2

15 The following example provides a preferred composition of the present invention. The composition is provided as two separate preparations: lozenge A (fish oil) and lozenge B (garlic, capsaicin, and rutin). The proper daily dosage is six of lozenge A and four of lozenge B (in other words, three of lozenge A and two of lozenge B taken twice daily for a total of ten lozenges).

20	Ingredient	Weight
	Lozenge A	1000 mg
	Fish Oil	1000 mg
	Lozenge B	700 mg
25	Garlic Powder	487 mg
	Capsaicin	53 mg
	Rutin	27 mg
	lemon bioflavonoid	23 mg
	parsley powder	110 mg

EXAMPLE 3

The following example provides a preferred composition of the present invention. The composition is provided as two separate preparations: Lozenge A (fish oil) and Lozenge B (garlic, capsaicin, rutin). The proper dosage is six capsules of Lozenge A each day and four capsules of Lozenge B (in other words, three of lozenge A and two of lozenge B taken twice daily for a total of ten lozenges).

	Ingredient	Weight
10	Lozenge A	950 mg
	Fish Oil	950 mg
	Lozenge B	700 mg
	Garlic Powder	600 mg
	Capsaicin	50 mg
15	Rutin	50 mg

EXAMPLE 4

The following example provides a preferred composition of the present invention. The composition is provided as a single preparation. The proper dosage is five capsules of the lozenge taken twice each day.

	Ingredient	Weight
	fish oil*	570 mg
	garlic powder	194 mg
	rutin	11 mg
25	capsaicin	21 mg
	lemon bioflavonoids	11 mg
	parsley powder	38 mg
	d-alpha tocopherol	5 mg
	bee's wax	75 mg
30	lecithin	75 mg
	gelatin	255 mg
	purified water	10 mg
	glycerin	170 mg

* fish oil in the form of 300:200 of EPA:DHA

Numerous modifications and variations of the present invention are included in the above-identified specification and are expected to be obvious to one of skill in the art. It is also intended that the present invention cover modifications and variations of the compositions and method for using them to accomplish their claimed uses within the scope of the appended claims and their equivalents.

WE CLAIM:

1. A nutritional supplement comprising fish oil, garlic, rutin, and capsaicin.

2. The nutritional supplement of claim 1, wherein the fish
5 oil is in the form of a single fish oil lozenge.

3. The nutritional supplement of claim 2, wherein the garlic, rutin, and capsaicin are in the form of a single garlic, rutin, and capsaicin lozenge.

4. The nutritional supplement of claim 1, wherein the fish
10 oil, garlic, rutin, and capsaicin are in the form of a single lozenge.

5. The nutritional supplement of claim 3, wherein the fish oil lozenge is between approximately 350 mg to approximately 650 mg.

15 6. The nutritional supplement of claim 5, wherein the fish oil lozenge is approximately 500 mg.

7. The nutritional supplement of claim 3, wherein the garlic is between approximately 200 mg to approximately 700 mg, the rutin is between approximately 10 mg to approximately 150 mg,
20 and the capsaicin is between approximately 20 mg to approximately 150 mg.

8. The nutritional supplement of claim 7, wherein the fish oil is approximately 500 mg, the garlic is approximately 500 mg, the rutin is approximately 100 mg, and the capsaicin is
25 approximately 100 mg.

9. The nutritional supplement of claim 7, wherein the fish oil is approximately 500 mg, the garlic is approximately 275 mg, the rutin is approximately 135 mg, and the capsaicin is

approximately 90 mg.

10. The nutritional supplement of claim 7, wherein the fish oil is approximately 600 mg, the garlic is approximately 200 mg, the rutin is approximately 10 mg, and the capsaicin is approximately 20 mg.

11. The nutritional supplement of claim 3, wherein the garlic, rutin, and capsaicin lozenge is between approximately 350 mg and approximately 650 mg.

12. The nutritional supplement of claim 7, wherein the garlic, rutin, and capsaicin lozenge is approximately 500 mg.

13. The nutritional supplement of claim 3, wherein the total weight of the fish oil and garlic, rutin, and capsaicin lozenges is between approximately 700 mg and approximately 1,300 mg.

14. The nutritional supplement of claim 13, wherein the total weight of the fish oil and garlic, rutin, and capsaicin lozenges is approximately 1,000 mg.

15. The nutritional supplement of claim 1, wherein the fish oil comprises between approximately 250 IU to approximately 350 IU EPA.

16. The nutritional supplement of claim 15, wherein the fish oil comprises approximately 300 IU EPA.

17. The nutritional supplement of claim 1, wherein the fish oil comprises between approximately 150 IU to approximately 250 IU DHA.

18. The nutritional supplement of claim 17, wherein the fish oil comprises approximately 200 IU DHA.

19. The nutritional supplement of claim 1, wherein the

garlic is in the form of garlic powder.

20. A method of preparing the nutritional supplement of the present invention comprising admixing the fish oil, garlic, rutin, and capsaicin components with a suitable carrier.

5 21. A method of increasing the levels of HDL in human blood plasma comprising administering daily the nutritional supplement of claim 3 or claim 4.

10 22. A method of decreasing the levels of O-LDL, cholesterol, and triglycerides in human blood plasma comprising administering daily the nutritional supplement of claim 3 or claim 4.


15 23. The method of claim 21, wherein the daily dosage is comprised of from approximately 4 to approximately 8 fish oil lozenges together with from approximately 3 to approximately 5 garlic, rutin, and capsaicin lozenges.

24. The method of claim 22, wherein the daily dosage is comprised of from approximately 4 to approximately 8 fish oil lozenges together with from approximately 3 to approximately 5 garlic, rutin, and capsaicin lozenges.

20 25. The method of claim 23 or claim 24, wherein the daily dosage is comprised of approximately 6 fish oil lozenges together with approximately 4 garlic, rutin, and capsaicin lozenges.

Figure 1

Effect of Fish Oil/ Garlic on Lipid Profile



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/10500

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 35/78, 31/70, 31/20, 31/16

US CL : 424/195.1; 514/27, 560, 627

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/195.1; 514/27, 560, 627

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPIDS, HCAPLUS, MEDLINE- GARLIC, FISH OILS, RUTIN AND CAPSAICIN FOR LOWERING OF CHOLESTEROL AND ETC.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4,680,313 A (IWA) 14 July 1987, see entire document.	1-25
Y	Database Hcaplus on STN, No. 1985:606162, NEGULESCO, J. A. et al. "Capsaicin Lowers Plasma Cholesterol and Triglycerides of Lagomorphs" abstract No. 103:206162, 1985.	1-25
Y	Database Wpids on STN, Derwent Information Ltd., AN 87-192446, BORRETZEN, B. et al. "Refined Fish Oil Concentrate Contg. Omega-three Fatty Acid Ester(s) - Used In Treating Thrombotic Illness And Lowering Blood Cholesterol Level," abstract No. WO 8703899 A , 1987.	1-25

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A" document defining the general state of the art which is not considered to be of particular relevance	*X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E" earlier document published on or after the international filing date	*Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*&"	document member of the same patent family
*O" document referring to an oral disclosure, use, exhibition or other means		
*P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

09 AUGUST 1996

Date of mailing of the international search report

03 OCT 1996

 Name and mailing address of the ISA/US
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

M. MOEZIE

Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/10500

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Database Wpids on STN, Derwent Information Ltd., AN 66-18025F, (MEDI-N) FAB MEDICINALI DURS, "Rutine Vitamin E Deriv Complexes," abstract, FR 3350 M, 1968.	1-25
Y	Database Wpids on STN, Derwent Information Ltd., AN 95-084298, (OTAT-I) OTA T, "Garlic Emulsion For Reducing Cholesterol Level And Preventing Hypertension, etc.- Is Prepared From Powder of Garlic, Fish Oil, Perilla Oil, And Stabiliser," abstract, JP07008201 A, 1995.	1-25

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.